PROTECT Study in IgAN: Topline Data

PROTECT Study in IgAN: Topline Data

ReachMD Healthcare Image
RestartResume

Our expert discusses the key two-year findings based on the final analysis of the double-blinded, active controlled phase 3 PROTECT Trial, evaluating the safety of sparsentan versus irbesartan in patients with IgA nephropathy.

  • Overview

    The two-year final analysis of the PROTECT trial showed sustained proteinuria reduction and one of the slowest rates of kidney function decline observed in IgAN trials in patients treated with sparsentan, non-immunosuppressive, dual endothelin angiotensin receptor antagonist (DEARA), versus irbesartan, an angiotensin II receptor blocker, highlighting sparsentan’s promising impact on preserving kidney function in patients with IgAN. Your patients will thank you for joining our expert, Dr. Jonathan Barratt in this PROTECT topline data analysis.

  • Provider(s)/Educational Partner(s)

      

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum. 

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

Facebook Comments

Register

We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free